Lutomski P et al
The primary endpoint was to demonstrate that orforglipron is superior to placebo in the maintenance of body weight reduction in participants who achieved plateau with either Zepbound or Wegovy in the SURMOUNT-5 trial
REFERENCES 1.Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, et al
18 Just as there are differences between the antihyperglycemic agents, there are inter-agent differences between the GLP-1 RAs, with established differences in their glucose-lowering, lipid-lowering and weight loss effects
There is a way to reach a real person for customer support not just an AI chatbot
Symptoms include difficulty breathing, swelling of the face or throat, and a rapid heartbeat